…Rabbit Antithymocyte Globulin versus Basiliximab for Induction in Renal Transplantation, showed that treatment with Thymoglobulin resulted in a significantly reduced risk of acute rejection and acute rejection requiring antibody therapy, and a similar risk of delayed graft function, graft loss and death.
The study, which involved 278 patients at high risk for acute rejection or delayed graft function following a kidney transplant from a deceased donor, wanted a composite measure of the first occurrence of four factors: acute rejection, delayed graft function, graft loss and death.
A product of Genzyme Corporation (Nasdaq: GENZ), Thymoglobulin® is an immunosuppressive product that contains cytotoxic antibodies directed against antigens expressed on human T-lymphocytes.
Find more details from the press release.
Comment Preview